Entheon Biomedical (XCNQ:ENBI) Change In Receivables : C$0.08 Mil (TTM As of Feb. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Change In Receivables?

Entheon Biomedical's change in receivables for the quarter that ended in Feb. 2024 was C$0.00 Mil. It means Entheon Biomedical's Accounts Receivable stayed the same from Nov. 2023 to Feb. 2024 .

Entheon Biomedical's change in receivables for the fiscal year that ended in Nov. 2023 was C$0.04 Mil. It means Entheon Biomedical's Accounts Receivable declined by C$0.04 Mil from Nov. 2022 to Nov. 2023 .

Entheon Biomedical's Accounts Receivable for the quarter that ended in Feb. 2024 was C$0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Entheon Biomedical's liquidation value for the three months ended in Feb. 2024 was C$0.20 Mil.

Entheon Biomedical Change In Receivables Historical Data

The historical data trend for Entheon Biomedical's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Change In Receivables Chart

Entheon Biomedical Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Nov21

Nov22

Nov23

Change In Receivables

Get a 7-Day Free Trial

-0.01

0.01

0.08

-0.01

0.04

Entheon Biomedical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Change In Receivables	Get a 7-Day Free Trial															-0.04	0.08	-	0.01	-

Entheon Biomedical Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.08 Mil.

Entheon Biomedical (XCNQ:ENBI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Entheon Biomedical's Days Sales Outstanding for the quarter that ended in Feb. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Entheon Biomedical's accounts receivable are only considered to be worth 75% of book value:

Entheon Biomedical's liquidation value for the quarter that ended in Feb. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.25	-	0.051	+	0.75 * 0	+	0.5 * 0
=	0.20

Entheon Biomedical Change In Receivables Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Entheon Biomedical (XCNQ:ENBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ENTBF:USA 1XU1:Germany

Address

999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5

Website

https://www.entheonbiomedical.com

Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines